ArticleEuropean journal of nuclear medicine and molecular imaging2011
PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT.
Article in European journal of nuclear medicine and molecular imaging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.The Cochrane database of systematic reviews · 2019Pooled it
- ¹⁸F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy.European journal of nuclear medicine and molecular imaging · 2012Trial
- Radiopharmaceuticals in Malignant Melanoma: A Comprehensive Review of Diagnostic, Therapeutic, and Immune-Related Applications by PET/CT, SPECT/CT, and PET/MRI.Diagnostics (Basel, Switzerland) · 2025Review
- Diagnostic Performance of [Cancers · 2024Review
- Comprehensive literature review of oral and intravenous contrast-enhanced PET/CT: a step forward?Frontiers in medicine · 2024Review
- The Role and Potential ofDiagnostics (Basel, Switzerland) · 2022Review
- Article
- Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm.Nature reviews. Clinical oncology · 2020Review
- Role of CT Density in PET/CT-Based Assessment of Lymphoma.Molecular imaging and biology · 2018Article
- The value of FDG PET/CT for follow-up of patients with melanoma: a retrospective analysis.American journal of nuclear medicine and molecular imaging · 2017Article
- The role of FDG-PET/CT in preoperative staging of sentinel lymph node biopsy-positive melanoma patients.EJNMMI research · 2016Article
- Pulmonary malignant melanoma with distant metastasis assessed by positron emission tomography-computed tomography.Thoracic cancer · 2016Article
- [Whole-body staging of malignant melanoma: advantages, limitations and current importance of PET-CT, whole-body MRI and PET-MRI].Der Radiologe · 2015Article
- Clinical impact of (18)F-FDG PET-CT in recurrent stage III/IV melanoma: a tertiary centre Specialist Skin Cancer Multidisciplinary Team (SSMDT) experience.Insights into imaging · 2013Article
- Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen?European radiology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to evaluate the diagnostic value of contrast-enhanced CT (CECT) versus non-enhanced low-dose CT (NECT) in the staging of advanced malignant melanoma with (18)F-fluordeoxyglucose (FDG) positron emission tomography (PET)/CT.
methodsIn total, 50 (18)F-FDG PET/CT examinations were performed in 50 patients with metastasized melanoma. For attenuation correction, whole-body NECT was performed followed by diagnostic CECT with contrast agent. For the whole-body PET, (18)F-FDG was applied. Criteria for evaluation were signs of vital tumour tissue (extent of lesions, contrast enhancement, maximum standardized uptake value >2.5). Findings suspicious for melanoma were considered lesions. NECT, CECT and (18)F-FDG PET were evaluated separately, followed by combined analysis of PET/NECT and PET/CECT. Findings were verified histologically and/or by follow-up (>6 months).
resultsOverall, 232 lesions were analysed, and 151 proved to be metastases. The sensitivity of NECT, CECT, PET, PET/NECT and PET/CECT was 62, 85, 90, 97 and 100%, and specificity was 52, 63, 88, 93 and 93%, respectively. Compared to CECT, NECT obtained additional false-negative results: lymph node (n = 19) and liver/spleen metastases (n = 9). Misinterpreted physiological structures mainly caused additional false-positive findings (n = 17). In combined analysis of PET/NECT, six false-positive [other tumours (n = 2), inflammatory lymph nodes (n = 2), inflammatory lung lesion (n = 1), blood vessel (n = 1)] and five false-negative findings [liver (n = 3), spleen (n = 1), lymph node metastases (n = 1)] remained. On PET/CECT, six false-positive [inflammatory lymph nodes (n = 3), other tumours (n = 2), inflammatory lung lesion (n = 1)] and no false-negative findings occurred. However, additional false findings on PET/NECT (6 of 232) did not change staging compared to PET/CECT.
conclusionOur results indicate that it is justified to perform PET/NECT instead of PET/CECT for melanoma staging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.